Pacira BioSciences, Inc. Common Stock PCRX
$36.39
+44.40%
at last close
Recent SEC Filings
| Form | Description | Filed | Document |
|---|---|---|---|
| 8-K | FORM 8-K | 2026-10-08 | View → |
| 4 | FORM 4 | 2026-08-18 | View → |
| 10-Q | 10-Q - PCRX - 06.30.2026 | 2026-08-04 | View → |
| 8-K | 8-K | 2026-08-04 | View → |
| 8-K | 8-K | 2026-06-30 | View → |
| 4 | FORM 4 | 2026-06-12 | View → |
| 4 | FORM 4 | 2026-06-12 | View → |
| 4 | FORM 4 | 2026-06-12 | View → |
| 4 | FORM 4 | 2026-06-12 | View → |
| 4 | FORM 4 | 2026-06-12 | View → |
| 4 | FORM 4 | 2026-06-12 | View → |
| 4 | FORM 4 | 2026-06-12 | View → |
| 4 | FORM 4 | 2026-06-12 | View → |
| 4 | FORM 4 | 2026-06-12 | View → |
| 8-K | 8-K | 2026-06-11 | View → |
| 4 | FORM 4 | 2026-06-05 | View → |
| 4 | FORM 4 | 2026-06-05 | View → |
| 4 | FORM 4 | 2026-06-05 | View → |
| 10-Q | 10-K - PCRX - 03.31.2026 | 2026-04-30 | View → |
| 8-K | 8-K | 2026-04-30 | View → |
| 4 | FORM 4 | 2026-04-24 | View → |
| 4 | FORM 4 | 2026-04-22 | View → |
| 4 | FORM 4 | 2026-03-19 | View → |
| 4 | FORM 4 | 2026-03-19 | View → |
| 10-K | 10-K - PCRX - 12.31.2025 | 2026-02-26 | View → |
| 8-K | 8-K | 2026-02-26 | View → |
| 4 | FORM 4 | 2026-02-13 | View → |
| 4 | FORM 4 | 2026-02-13 | View → |
| 4 | FORM 4 | 2026-02-13 | View → |
| 4 | FORM 4 | 2026-02-13 | View → |
| 4 | FORM 4 | 2026-02-13 | View → |
| 4 | FORM 4 | 2026-02-13 | View → |
| 4 | FORM 4 | 2026-02-03 | View → |
| 4 | FORM 4 | 2026-02-03 | View → |
| 4 | FORM 4 | 2026-02-03 | View → |
| 4 | FORM 4 | 2026-02-03 | View → |
| 4 | FORM 4 | 2026-02-03 | View → |
| 4 | FORM 4 | 2026-01-29 | View → |
| 8-K | 8-K | 2026-01-28 | View → |
| 8-K | 8-K | 2026-01-08 | View → |
Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.
Key Stats
- Last Close
- $36.39
- Market Cap
- $1.00 billion
- 52-Week Range
- $18.80 – $36.46
- Average Volume
- 1.50 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.